Skip to main content
. 2022 Feb 28;10(3):378. doi: 10.3390/vaccines10030378

Figure 5.

Figure 5

Structure characterisation of model vaccine with TLR4-agonist adjuvant (A) amino acid sequence, (B) 3D structure of 50S Ribosomal protein L7/L12 vaccine, (C) Ramachandran plot, (D) secondary structure elements, (E) original versus mutated structure, and (F) cloned vaccine into expression vector.